Back to News
Market Impact: 0.2
Prelude, Lilly Partner On Breast Cancer Combination Trial; Stock Up
Source: Nasdaq
Healthcare & Biotech
Prelude Therapeutics announced a clinical trial collaboration with Eli Lilly to evaluate PRT13722 in combination with Verzenio (abemaciclib) and Inluriyo (imlunestrant) in patients with HR+/HER2- breast cancer. The announcement provides no trial results or financial terms.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
LLY0.15
PRLD0.50
More News
- J&J's 6% slide on an imperfect quarter is a gift to prospective buyers
- Walmart to cover some GLP-1s, inhalers and insulin for employees at no cost as it expands benefits
- Evercore ISI cuts Foghorn Therapeutics stock rating on trial failure
- UnitedHealth Group tops estimates, hikes profit outlook as insurer manages high medical costs
- J&J beats earnings estimates; Middle East conflict weighs on medical-device sales
- Rhythm Pharmaceuticals launches IMCIVREE in Japan for obesity